BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30099968)

  • 1. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease.
    Alexander M; Loomis AK; Fairburn-Beech J; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Avillach P; Egger P; Kendrick S; Waterworth DM; Sattar N; Alazawi W
    BMC Med; 2018 Aug; 16(1):130. PubMed ID: 30099968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Avillach P; Egger P; Dhalwani NN; Kendrick S; Celis-Morales C; Waterworth DM; Alazawi W; Sattar N
    BMJ; 2019 Oct; 367():l5367. PubMed ID: 31594780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis.
    Liu J; Tian Y; Fu X; Mu C; Yao M; Ni Y; Liu Y; Li Z
    Chin Med J (Engl); 2022 Jul; 135(14):1682-1691. PubMed ID: 36070463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
    Younossi ZM; Koenig AB; Abdelatif D; Fazel Y; Henry L; Wymer M
    Hepatology; 2016 Jul; 64(1):73-84. PubMed ID: 26707365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
    Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
    J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.
    Li J; Zou B; Yeo YH; Feng Y; Xie X; Lee DH; Fujii H; Wu Y; Kam LY; Ji F; Li X; Chien N; Wei M; Ogawa E; Zhao C; Wu X; Stave CD; Henry L; Barnett S; Takahashi H; Furusyo N; Eguchi Y; Hsu YC; Lee TY; Ren W; Qin C; Jun DW; Toyoda H; Wong VW; Cheung R; Zhu Q; Nguyen MH
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):389-398. PubMed ID: 30902670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.
    Riazi K; Azhari H; Charette JH; Underwood FE; King JA; Afshar EE; Swain MG; Congly SE; Kaplan GG; Shaheen AA
    Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):851-861. PubMed ID: 35798021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    Kakisaka K; Suzuki Y; Fujiwara Y; Abe T; Yonezawa M; Kuroda H; Ishida K; Sugai T; Takikawa Y
    J Gastroenterol; 2018 Dec; 53(12):1285-1291. PubMed ID: 29680867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
    Papatheodoridi M; Cholongitas E
    Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of non-alcoholic fatty liver disease.
    Bellentani S; Scaglioni F; Marino M; Bedogni G
    Dig Dis; 2010; 28(1):155-61. PubMed ID: 20460905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
    García-Monzón C; Vargas-Castrillón J; Porrero JL; Alonso MT; Bonachía O; Castillo MJ; Marcos A; Quirós E; Ramos B; Sánchez-Cabezudo C; Villar S; Sáez A; Rodríguez de Cía J; del Pozo E; Vega-Piris L; Soto-Fernández S; Lo Iacono O; Miquilena-Colina ME
    Liver Int; 2015 Aug; 35(8):1983-91. PubMed ID: 25708133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
    Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
    Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
    Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M
    Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.